Jiangsu Hengrui Sets 2025 Final Dividend and Record Date for H Shareholders

An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals has approved a 2025 final cash dividend of RMB2 per 10 shares, payable in Renminbi for A shares and in Hong Kong dollars for H shares based on a set exchange rate, resulting in HK$2.2828 per 10 H shares. The dividend will be distributed to H share investors on 27 May 2026, with eligibility determined by a 11 May record date and an associated register closure period.

Shares held in the company’s stock repurchase account, including any repurchased but not yet cancelled or treasury shares, will not be entitled to the payout, and the total distribution amount will be adjusted if the share capital changes before the record date. Non-resident enterprise H share holders will face a 10% withholding tax on the dividend, clarifying after-tax returns for institutional and overseas investors and underscoring standard tax treatment for cross-border equity income in the PRC.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong and Shanghai, focusing on the research, development and production of innovative and generic drugs. It serves both domestic A share investors and international H share investors, reflecting a dual-market capital structure common among major Chinese healthcare issuers.

Average Trading Volume: 3,291,704

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$438.2B

See more insights into 1276 stock on TipRanks’ Stock Analysis page.